


## CLAIMS

We claim:

1. A compound of Formula (I):



or a salt, solvate, or physiologically functional derivative thereof;

wherein:

D<sub>1</sub> is aryl, heteroaryl, or heterocyclic said aryl, heteroaryl and heterocyclic groups being optionally substituted with at least one group R;

R is independently selected from the group consisting of halo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, -NR<sup>1</sup>R<sup>2</sup>, C<sub>1</sub>-C<sub>4</sub> haloalkyl, hydroxy, -C(O)R<sup>1</sup>, -OC(O)R<sup>1</sup>, -C(O)NR<sup>1</sup>R<sup>2</sup>, -S(O)<sub>2</sub>R<sup>1</sup>, C<sub>1</sub>-C<sub>6</sub> alkylsulfanyl, cyano, C<sub>1</sub>-C<sub>2</sub> halalkoxy, or the group defined by -(Y)<sub>0</sub>-(Y<sup>1</sup>)<sub>r</sub>-(Y<sup>2</sup>);

wherein:

Y is O and o is 0 or 1;

Y<sup>1</sup> is C(H)(R'), and r is 0, 1, 2, 3, or 4; and

Y<sup>2</sup> is aryl, heteroaryl, heterocyclic, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, or C<sub>2</sub>-C<sub>6</sub> alkenyl;

D<sub>2</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

D<sub>3</sub> is aryl or heteroaryl said aryl or heteroaryl groups being optionally substituted with at least one group Q;

Q is independently selected from the group consisting of halo, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, hydroxy, aralkoxy, C<sub>1</sub>-C<sub>6</sub> alkenyl, alkynyl, C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl, cyano, aryloxy, C<sub>1</sub>-C<sub>2</sub> halalkoxy, -NO<sub>2</sub>, or -C(O)OR<sup>1</sup>, or the group defined by -(Z)<sub>q</sub>-(Z<sup>1</sup>)<sub>r</sub>-(Z<sup>2</sup>),

wherein:

Z is NH and q is 0 or 1; or

Z is CH<sub>2</sub> and q is 0, 1, 2, or 3; or

Z is O(CH<sub>2</sub>)<sub>n</sub>, where n is 1, 2, 3, or 4 and q is 0 or 1;

Z<sup>1</sup> is S(O)<sub>2</sub> or C(O); and r is 0 or 1, and

Z<sup>2</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, heteroaryl, heterocyclic, hydroxy, halo, aralkyl, C<sub>1</sub>-C<sub>2</sub> haloalkyl, C(H)(R')R<sup>3</sup>, NH(CH<sub>2</sub>)<sub>n</sub>NR<sup>1</sup>R<sup>2</sup>, NH(CH<sub>2</sub>)<sub>n</sub>R<sup>3</sup>, NH(CH<sub>2</sub>)<sub>n</sub>OR<sup>1</sup> or NR<sup>1</sup>R<sup>2</sup> where n is 1, 2, 3, or 4 ;


R<sup>1</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, aryl, heteroaryl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, heterocyclic, or aralkyl;

R<sup>2</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, aryl, heteroaryl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, heterocyclic, or aralkyl;

R<sup>3</sup> is heteroaryl or heterocyclic, and

R' is hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl.

2. A compound of Formula (I):




or a salt, solvate, or physiologically functional derivative thereof;

wherein:

D<sub>1</sub> is

190



where

X is selected from N, O, or S;X<sub>a</sub> is N and X<sub>b</sub> is N, O, or S, orX<sub>a</sub> is O and X<sub>b</sub> is N, orX<sub>a</sub> is S and X<sub>b</sub> is N;m is 0, 1, 2, 3, or 4;

R is independently selected from the group consisting of halo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, -NR<sup>1</sup>R<sup>2</sup>, C<sub>1</sub>-C<sub>4</sub> haloalkyl, hydroxy, -C(O)R<sup>1</sup>, -OC(O)R<sup>1</sup>, -C(O)NR<sup>1</sup>R<sup>2</sup>, -S(O)<sub>2</sub>R<sup>1</sup>, C<sub>1</sub>-C<sub>6</sub> alkylsulfanyl, cyano, C<sub>1</sub>-C<sub>2</sub> halalkoxy, or  
the group defined by -(Y)<sub>o</sub>-(Y<sup>1</sup>)<sub>r</sub>-(Y<sup>2</sup>);

wherein:


Y is O and o is 0 or 1;

$Y^1$  is  $C(H)(R')$ , and  $r$  is 0, 1, 2, 3, or 4; and

$Y^2$  is aryl, heteroaryl, heterocyclic,  $C_3-C_7$  cycloalkyl, or  $C_2-C_6$  alkenyl;

$D_2$  is hydrogen or  $C_1-C_4$  alkyl;

$D_3$  is selected from the group



where  $X$  is selected from N, O, or S, and

$p$  is 0, 1, 2, 3, 4, or 5;

$Q$  is independently selected from the group consisting of halo,  $C_1-C_4$  haloalkyl,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy,  $C_1-C_4$  haloalkoxy, hydroxy, aralkoxy,  $C_1-C_6$  alkenyl, alkynyl,  $C_1-C_4$  hydroxyalkyl, cyano, aryloxy,  $C_1-C_2$  halalkoxy,  $-NO_2$ , or  $-C(O)OR^1$ , or the group defined by  $-(Z)_q-(Z^1)_r-(Z^2)$ ,

wherein:

$Z$  is NH and  $q$  is 0 or 1; or

$Z$  is  $CH_2$  and  $q$  is 0, 1, 2, or 3; or

$Z$  is  $O(CH_2)_n$  where  $n$  is 1, 2, 3, or 4 and  $q$  is 0 or 1;

$Z^1$  is  $S(O)_2$  or  $C(O)$ ; and  $r$  is 0 or 1, and

$Z^2$  is  $C_1-C_6$  alkyl, aryl, heteroaryl, heterocyclic, hydroxy, halo, aralkyl,  $C_1-C_2$  haloalkyl,  $C(H)(R')R^3$ ,  $NH(CH_2)_nNR^1R^2$ ,  $NH(CH_2)_nR^3$ ,  $NH(CH_2)_nOR^1$  or  $NR^1R^2$ ; where  $n$  is 1, 2, 3, or 4;


$R^1$  is hydrogen,  $C_1-C_4$  alkyl,  $C_2-C_6$  alkenyl,  $C_2-C_6$  alkynyl, aryl, heteroaryl,  $C_3-C_7$  cycloalkyl, heterocyclic, or aralkyl;

$R^2$  is hydrogen,  $C_1-C_4$  alkyl,  $C_2-C_6$  alkenyl,  $C_2-C_6$  alkynyl, aryl, heteroaryl,  $C_3-C_7$  cycloalkyl, heterocyclic, or aralkyl;

$R^3$  is heteroaryl or heterocyclic, and

$R'$  is hydrogen or  $C_1-C_3$  alkyl.

## 3. A compound of Formula (II):



or a salt, solvate, or physiologically functional derivative thereof;

wherein:

*m* is 0, 1, 2, 3, or 4;

*p* is 0, 1, 2, 3, 4, or 5;

*R* is independently selected from the group consisting of halo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, -NR<sup>1</sup>R<sup>2</sup>, C<sub>1</sub>-C<sub>4</sub> haloalkyl, hydroxy, -C(O)R<sup>1</sup>, -OC(O)R<sup>1</sup>, -C(O)NR<sup>1</sup>R<sup>2</sup>, -S(O)<sub>2</sub>R<sup>1</sup>, C<sub>1</sub>-C<sub>6</sub> alkylsulfanyl, cyano, C<sub>1</sub>-C<sub>2</sub> halalkoxy, or the group defined by -(Y)<sub>o</sub>-(Y<sup>1</sup>)<sub>r</sub>-(Y<sup>2</sup>);

wherein:

*Y* is O and *o* is 0 or 1;

*Y*<sup>1</sup> is C(H)(R<sup>1</sup>), and *r* is 0, 1, 2, 3, or 4; and

*Y*<sup>2</sup> is aryl, heteroaryl, heterocyclic, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, or C<sub>2</sub>-C<sub>6</sub> alkenyl;

---

*Q* is independently selected from the group consisting of halo, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, hydroxy, aralkoxy, C<sub>1</sub>-C<sub>6</sub> alkenyl, alkynyl, C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl, cyano, aryloxy, C<sub>1</sub>-C<sub>2</sub> halalkoxy, -NO<sub>2</sub>, or -C(O)OR<sup>1</sup>, or the group defined by -(Z)<sub>q</sub>-(Z<sup>1</sup>)<sub>r</sub>-(Z<sup>2</sup>),

wherein:

*Z* is NH and *q* is 0 or 1; or

*Z* is CH<sub>2</sub> and *q* is 0, 1, 2, or 3; or

*Z* is O(CH<sub>2</sub>)<sub>n</sub> where *n* is 1, 2, 3, or 4 and *q* is 0 or 1;

*Z*<sup>1</sup> is S(O)<sub>2</sub> or C(O); and *r* is 0 or 1, and

$Z^2$  is  $C_1\text{-}C_6$  alkyl, aryl, heteroaryl, heterocyclic, hydroxy, halo, aralkyl,  $C_1\text{-}C_2$  haloalkyl,  $C(H)(R')R^3$ ,  $NH(CH_2)_nNR^1R^2$ ,  $NH(CH_2)_nR^3$ ,  $NH(CH_2)_nOR^1$  or  $NR^1R^2$ , where  $n$  is 1, 2, 3, or 4;


$R^1$  is hydrogen,  $C_1\text{-}C_4$  alkyl,  $C_2\text{-}C_6$  alkenyl,  $C_2\text{-}C_6$  alkynyl, aryl, heteroaryl,  $C_3\text{-}C_7$  cycloalkyl, heterocyclic, or aralkyl;

$R^2$  is hydrogen,  $C_1\text{-}C_4$  alkyl,  $C_2\text{-}C_6$  alkenyl,  $C_2\text{-}C_6$  alkynyl, aryl, heteroaryl,  $C_3\text{-}C_7$  cycloalkyl, heterocyclic, or aralkyl;

$R^3$  is heteroaryl or heterocyclic, and

$R'$  is hydrogen or  $C_1\text{-}C_3$  alkyl.

4. A compound of Formula (III):



or a salt, solvate, or physiologically functional derivative thereof;

wherein:

$R$  is independently selected from the group consisting of  $C_1\text{-}C_6$  alkoxy, hydroxy,  $C_1\text{-}C_6$  alkylsulfanyl,  $C_1\text{-}C_2$  haloalkoxy, or

the group defined by  $-(Y)_o-(Y^1)--(Y^2)$ ;

wherein:

$Y$  is O and  $o$  is 0 or 1;

$Y^1$  is  $C(H)(R')$ , and  $r$  is 0, 1, 2, 3, or 4; and

$Y^2$  is aryl, heteroaryl, heterocyclic, or  $C_3\text{-}C_7$  cycloalkyl;

$Q_2$  is hydrogen,  $C_1\text{-}C_6$  alkyl,  $C_2\text{-}C_6$  alkenyl,  $C_2\text{-}C_6$  alkynyl, halo, cyano, or  $C_1\text{-}C_4$  haloalkyl;

$Q_3$  is hydrogen or

the group defined by  $-(Z)_q-(Z^1)_r-(Z^2)$ ,

wherein:

$Z$  is  $\text{CH}_2$  and  $q$  is 0, 1, or 2; or

$Z$  is  $\text{O}(\text{CH}_2)_n$  where  $n$  is 1, 2, 3, or 4 and  $q$  is 0 or 1;

$Z^1$  is  $\text{C}(\text{O})$ ; and  $r$  is 0 or 1, and

$Z^2$  is  $\text{NH}(\text{CH}_2)_n\text{NR}^1\text{R}^2$  or  $\text{NR}^1\text{R}^2$ , where  $n$  is 1, 2, 3, or 4;

$R^1$  is hydrogen,  $C_1\text{-}C_4$  alkyl,  $C_2\text{-}C_6$  alkenyl,  $C_2\text{-}C_6$  alkynyl, aryl, heteroaryl,  $C_3\text{-}C_7$  cycloalkyl, heterocyclic, or aralkyl;

$R^2$  is hydrogen,  $C_1\text{-}C_4$  alkyl,  $C_2\text{-}C_6$  alkenyl,  $C_2\text{-}C_6$  alkynyl, aryl, heteroaryl,  $C_3\text{-}C_7$  cycloalkyl, heterocyclic, or aralkyl;

$R^3$  is heteroaryl or heterocyclic;

$R'$  is hydrogen or  $C_1\text{-}C_3$  alkyl; and

$X$  is CH or N.

5. A compound as claimed in claim 1, selected from the group consisting of:

5-(3-methoxyphenyl)-*N*-phenyl-1,3-oxazol-2-amine;

3-(2-anilino-1,3-oxazol-5-yl)phenol;

*N*-[4-(4-methylpiperazin-1-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine;

5-(3-methoxyphenyl)-*N*-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;

*N*-[4-(4-ethylpiperazin-1-yl)phenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

*N*-[4-(4-ethylpiperazin-1-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine;

*N*-[4-(morpholin-4-ylmethyl)phenyl]-5-phenyl-1,3-oxazol-2-amine;

5-(3-methoxyphenyl)-*N*-(4-morpholin-4-ylphenyl)-1,3-oxazol-2-amine;

5-(3-methoxyphenyl)-*N*-(4-piperidin-1-ylphenyl)-1,3-oxazol-2-amine;

5-(3-methoxyphenyl)-*N*-[4-(morpholin-4-ylmethyl)phenyl]-1,3-oxazol-2-amine;

5-(3-ethoxyphenyl)-*N*-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;  
5-(3-isopropoxyphenyl)-*N*-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;  
5-[3-(cyclopentyloxy)phenyl]-*N*-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;  
5-(3-isobutoxyphenyl)-*N*-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;  
5-[3-(benzyloxy)phenyl]-*N*-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;  
*N*-[4-(4-methylpiperazin-1-yl)phenyl]-5-{3-[(2-methylprop-2-enyl)oxy]phenyl}-1,3-oxazol-2-amine;  
*N*-[4-(4-methylpiperazin-1-yl)phenyl]-5-(3-propoxypyhenyl)-1,3-oxazol-2-amine;  
5-[3-(cyclohexyloxy)phenyl]-*N*-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;  
*N*-[3-chloro-4-(4-methylpiperazin-1-yl)phenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;  
*N*-[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;  
5-(3-methoxyphenyl)-*N*-[4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-oxazol-2-amine;  
5-(3-methoxyphenyl)-*N*-[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;  
*N*-[4-(3,5-dimethylpiperazin-1-yl)phenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;  
~~5-(3-methoxyphenyl)-*N*-[2-methyl-4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;~~  
5-[3-(cyclopentyloxy)phenyl]-*N*-[4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-oxazol-2-amine;  
*N*-[3-chloro-4-(4-methylpiperazin-1-yl)phenyl]-5-[3-(cyclopentyloxy)phenyl]-1,3-oxazol-2-amine;  
5-[3-(cyclopentyloxy)phenyl]-*N*-[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;

5-[3-(cyclopentyloxy)phenyl]-*N*-[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;

3-(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,3-oxazol-5-yl)phenol;

5-[3-(cyclopentyloxy)phenyl]-*N*-(4-thiomorpholin-4-ylphenyl)-1,3-oxazol-2-amine;

*N*-[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]-6-(4-methylpiperazin-1-yl)pyridin-3-amine;

6-(1*H*-imidazol-1-yl)-*N*-[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]pyridin-3-amine;

*N*-[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]-6-piperidin-1-ylpyridin-3-amine;

*N*-{5-[3-(cyclopentyloxy)phenyl]-1,3-oxazol-2-yl}-6-(4-methylpiperazin-1-yl)pyridin-3-amine;

*N*<sup>2</sup>,*N*<sup>2</sup>-diethyl-*N*<sup>6</sup>-[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]pyridine-2,5-diamine;

*N*<sup>6</sup>-{5-[3-(cyclopentyloxy)phenyl]-1,3-oxazol-2-yl}-*N*<sup>2</sup>,*N*<sup>2</sup>-diethylpyridine-2,5-diamine;

*N*-{5-[3-(cyclopentyloxy)phenyl]-1,3-oxazol-2-yl}-5-methyl-6-(4-methylpiperazin-1-yl)pyridin-3-amine;

5-(3-methoxyphenyl)-*N*-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-1,3-oxazol-2-amine;

*N*-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-5-phenyl-1,3-oxazol-2-amine;

*N*-{4-[(dimethylamino)methyl]phenyl}-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

5-[3-(cyclopentyloxy)phenyl]-*N*-{4-[(dimethylamino)methyl]phenyl}-1,3-oxazol-2-amine;

*N*-{4-[2-(dimethylamino)ethyl]phenyl}-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

5-(3-methoxyphenyl)-*N*-[4-(piperidin-1-ylmethyl)phenyl]-1,3-oxazol-2-amine;

5-(3-methoxyphenyl)-*N*-[4-(pyrrolidin-1-ylmethyl)phenyl]-1,3-oxazol-2-amine;

*N*-{4-[(diethylamino)methyl]phenyl}-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

*N*-[2-(diethylamino)ethyl]-4-{[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]amino}benzamide;

5-(3-methoxyphenyl)-*N*-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-1,3-oxazol-2-amine;

4-{[5-[3-(cyclopentyloxy)phenyl]-1,3-oxazol-2-yl}amino)-*N*-[2-(diethylamino)ethyl]benzamide;

5-(3-methoxyphenyl)-*N*-[4-(1-propylpiperidin-4-yl)-1,3-thiazol-2-yl]-1,3-oxazol-2-amine;

*N*,5-diphenyl-1,3-oxazol-2-amine;

*N*-methyl-1-{4-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl}methanesulfonamide;

*N*-{4-[(methylsulfonyl)methyl]phenyl}-5-phenyl-1,3-oxazol-2-amine;

*N,N*-diethyl-4-methoxy-3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide;

*N*-butyl-4-methoxy-3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide;

*N*-(3,4-dimethoxyphenyl)-5-phenyl-1,3-oxazol-2-amine;

*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-phenyl-1,3-oxazol-2-amine;

5-phenyl-*N*-[3-(phenylsulfonyl)phenyl]-1,3-oxazol-2-amine;

*N,N*-diethyl-4-[(5-phenyl-1,3-oxazol-2-yl)amino]benzamide;

4-(ethylsulfonyl)-2-[(5-phenyl-1,3-oxazol-2-yl)amino]phenol;

*N*-(2-methoxyphenyl)-5-phenyl-1,3-oxazol-2-amine;

*N*-butyl-3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide;

*N,N*-dimethyl-4-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide;

---

2,5-dimethoxy-4-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide;

*N*-(2-methoxy-5-nitrophenyl)-5-phenyl-1,3-oxazol-2-amine;

2-{4-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl}ethanol;

1-{4-methoxy-3-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl}ethanone;

{3-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl}methanol;

*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

4-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenol;  
3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-N,N-dimethylbenzenesulfonamide;  
*N*-{5-(ethylsulfonyl)-2-[2-(1*H*-imidazol-1-yl)ethoxy]phenyl}-5-(4-fluorophenyl)-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-(2-pyridin-2-ylethoxy)phenyl]-5-phenyl-1,3-oxazol-2-amine;  
*N*-{5-(ethylsulfonyl)-2-[2-(1*H*-1,2,3-triazol-1-yl)ethoxy]phenyl}-5-phenyl-1,3-oxazol-2-amine;  
5-phenyl-*N*-(3,4,5-trimethoxyphenyl)-1,3-oxazol-2-amine;  
*N*-(2,5-dimethoxyphenyl)-5-phenyl-1,3-oxazol-2-amine;  
3-methyl-5-[(5-phenyl-1,3-oxazol-2-yl)amino]benzene-1,2-diol;  
*N*-(3,5-dimethoxyphenyl)-5-phenyl-1,3-oxazol-2-amine;  
*N*-(3-methylphenyl)-5-phenyl-1,3-oxazol-2-amine;  
*N*-{3-[2-(1*H*-imidazol-1-yl)ethoxy]-4-methoxyphenyl}-5-phenyl-1,3-oxazol-2-amine;  
*N*-{4-[2-(1*H*-imidazol-1-yl)ethoxy]-3-methoxyphenyl}-5-phenyl-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine;  
5-(4-fluorophenyl)-*N*-{2-methoxy-5-[(methylsulfonyl)methyl]phenyl}-1,3-oxazol-2-amine;  
-----  
*N*-(5-{[5-(3-iodophenyl)-1,3-oxazol-2-yl]amino}-2-methylphenyl)methanesulfonamide;  
3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-*N*,*N*-dimethylbenzenesulfonamide;  
*N*-[3-(ethylsulfonyl)phenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine;  
3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-(pyridin-2-ylmethyl)benzenesulfonamide;  
5-(4-fluorophenyl)-*N*-[2-methoxy-5-(methylsulfonyl)phenyl]-1,3-oxazol-2-amine;

*N*-{2-methoxy-5-[(2-pyridin-2-ylethyl)sulfonyl]phenyl}-5-phenyl-1,3-oxazol-2-amine;

3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonamide;

*N*-{5-[(1-ethylpropyl)sulfonyl]-2-methoxyphenyl}-5-(4-fluorophenyl)-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-(2-methoxy-5-{[(5-methylisoxazol-3-yl)methyl]sulfonyl}phenyl)-1,3-oxazol-2-amine;

3-{[5-(3-bromophenyl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonamide;

5-(4-fluorophenyl)-*N*-[5-(isobutylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-{2-methoxy-5-[(tetrahydrofuran-2-ylmethyl)sulfonyl]phenyl}-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-[2-methoxy-5-(tetrahydrofuran-3-ylsulfonyl)phenyl]-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-(2-methoxy-5-{[2-(4-methyl-1,3-thiazol-5-yl)ethyl]sulfonyl}phenyl)-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-[5-(isopropylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

5-(3-bromophenyl)-*N*-[5-(isopropylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-(5-{[2-(1*H*-imidazol-1-yl)ethyl]sulfonyl}-2-methoxyphenyl)-1,3-oxazol-2-amine;

5-(3-bromophenyl)-*N*-(2-methoxy-5-{[2-(4-methyl-1,3-thiazol-5-yl)ethyl]sulfonyl}phenyl)-1,3-oxazol-2-amine;

*N*-(2-ethoxyphenyl)-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

*N*-(3,4-dimethoxyphenyl)-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

*N*-(3,4-dimethoxyphenyl)-5-(4-fluorophenyl)-1,3-oxazol-2-amine;

*N*-(3,4-dimethoxyphenyl)-5-(4-methylphenyl)-1,3-oxazol-2-amine;

5-(3,4-dichlorophenyl)-*N*-(3,4-dimethoxyphenyl)-1,3-oxazol-2-amine;

5-[4-(diethylamino)phenyl]-*N*-(3,4-dimethoxyphenyl)-1,3-oxazol-2-amine;

5-(4-chloro-3-methylphenyl)-*N*-(3,4-dimethoxyphenyl)-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine;  
5-(3,4-difluorophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
4-chloro-3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-*N,N*-dimethylbenzenesulfonamide;  
4-chloro-*N,N*-diethyl-3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;  
5-(4-fluorophenyl)-*N*-[3-(methylsulfonyl)phenyl]-1,3-oxazol-2-amine;  
*N*-[2-chloro-5-(methylsulfonyl)phenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine;  
*N*-[2-chloro-5-(ethylsulfonyl)phenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine;  
5-(4-fluorophenyl)-*N*-(3,4,5-trimethoxyphenyl)-1,3-oxazol-2-amine;  
5-(3-bromophenyl)-*N*-(3,4,5-trimethoxyphenyl)-1,3-oxazol-2-amine;  
5-(1,1'-biphenyl-3-yl)-*N*-(3,4,5-trimethoxyphenyl)-1,3-oxazol-2-amine;  
4-methoxy-*N*-(2-morpholin-4-ylethyl)-3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide;  
3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-(3-pyrrolidin-1-ylpropyl)benzenesulfonamide;  
3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-*N*-[3-(1*H*-imidazol-1-yl)propyl]-4-methoxybenzenesulfonamide;  
3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-(pyridin-3-ylmethyl)benzenesulfonamide;  
3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-(pyridin-4-ylmethyl)benzenesulfonamide;  
3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-*N*-isopropyl-4-methoxybenzenesulfonamide;  
3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-(tetrahydrofuran-2-ylmethyl)benzenesulfonamide;

5-(4-fluorophenyl)-*N*-[2-methoxy-5-(morpholin-4-ylsulfonyl)phenyl]-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-{2-methoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-[2-methoxy-5-(thiomorpholin-4-ylsulfonyl)phenyl]-1,3-oxazol-2-amine;

*N*-(cyclopropylmethyl)-3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonamide;

3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-(3-methoxypropyl)benzenesulfonamide;

3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-methylbenzenesulfonamide;

*N*-(2-ethoxyethyl)-3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonamide;

*N*-[5-(isopropylsulfonyl)-2-methoxyphenyl]-5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-amine;

*N*-[2-methoxy-5-(tetrahydrofuran-3-ylsulfonyl)phenyl]-5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-amine;

*N*-[5-(isobutylsulfonyl)-2-methoxyphenyl]-5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-amine;

5-(1,1'-biphenyl-3-yl)-*N*-{2-methoxy-5-[(1-pyridin-4-ylethyl)sulfonyl]phenyl}-1,3-oxazol-2-amine;

*N*-{2-methoxy-5-[(tetrahydrofuran-2-ylmethyl)sulfonyl]phenyl}-5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-amine;

*N*-(2-methoxy-5-{[2-(4-methyl-1,3-thiazol-5-yl)ethyl]sulfonyl}phenyl)-5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-amine;

5-(4-chlorophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

4-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)benzonitrile;

4-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)benzamide;

5-(4-bromophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-methyl-1-benzothien-2-yl)-1,3-oxazol-2-amine;  
5-(3-bromophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
5-(3-chlorophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-pyridin-3-yl-1,3-oxazol-2-amine;  
3-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)benzonitrile;  
3-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)benzamide;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-fluorophenyl)-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[4-(trifluoromethyl)phenyl]-1,3-oxazol-2-amine;  
5-(3,4-dichlorophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
5-(4-chloro-3-methylphenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
5-[5-(2,4-dichlorophenyl)-2-furyl]-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(2-naphthyl)-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-1,3-oxazol-2-amine;  
5-(2,3-dihydro-1,4-benzodioxin-6-yl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
5-(3,5-difluorophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-trifluoromethylphenyl)-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[4-(methylsulfonyl)phenyl]-1,3-oxazol-2-amine;  
5-(3,4-dimethoxyphenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

5-(3,4-dihydro-2*H*-1,5-benzodioxepin-7-yl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
5-(5-chlorothien-2-yl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
methyl 3-{[5-(3-bromophenyl)-1,3-oxazol-2-yl]amino}-4-methoxybenzoate;  
3-{[5-(3-bromophenyl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonyl fluoride;  
3-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenyl benzoate;  
3-(2-{[5-(ethylsulfonyl)-2-methylphenyl]amino}-1,3-oxazol-5-yl)phenol;  
5-[3-(cyclopropylmethoxy)phenyl]-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
5-(3-butoxyphenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(pyridin-2-ylmethoxy)phenyl]-1,3-oxazol-2-amine;  
5-(3-benzyloxyphenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(tetrahydro-2*H*-pyran-4-yloxy)phenyl]-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-pyridin-2-ylethoxy)phenyl]-1,3-oxazol-2-amine;  
5-{3-[(2,3-dimethoxybenzyl)oxy]phenyl}-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(1-pyridin-4-ylethoxy)phenyl]-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(tetrahydrofuran-3-yloxy)phenyl]-1,3-oxazol-2-amine;  
5-{3-[(2-chloropyrimidin-4-yl)oxy]phenyl}-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
4-[3-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenoxy]-*N*-isopropylpyrimidin-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-phenoxyphenyl)-1,3-oxazol-2-amine;

5-(3',5'-difluoro-1,1'-biphenyl-3-yl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-thien-2-ylphenyl)-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-thien-3-ylphenyl)-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-pyridin-3-ylphenyl)-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-vinylphenyl)-1,3-oxazol-2-amine;  
5-(3-ethylphenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-pyridin-4-ylphenyl)-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(1-methyl-1*H*-imidazol-5-yl)phenyl]-1,3-oxazol-2-amine;  
5-(1,1'-biphenyl-3-yl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-furyl)phenyl]-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-pyrazin-2-ylphenyl)-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(4'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-amine;  
5-[3-(2,3-dihydro-1-benzofuran-5-yl)phenyl]-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;  
*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(1,3-thiazol-2-yl)phenyl]-1,3-oxazol-2-amine;  
4-methoxy-3-{[5-(3-pyridin-3-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;  
3-{[5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonamide;  
4-methoxy-3-({5-[3-(1-methyl-1*H*-imidazol-5-yl)phenyl]-1,3-oxazol-2-yl}amino)benzenesulfonamide;  
3-{[5-(4'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-methylbenzenesulfonamide;

methyl 4-methoxy-3-{{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzoate; 3-{{[5-(4'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonamide; N-{{5-[(1-ethylpropyl)sulfonyl]-2-methoxyphenyl}-5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-amine; 1-[3-(2-{{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenyl]ethanone; 1-[4-(2-{{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenyl]ethanone; 4-methoxy-3-{{[5-(3-pyridin-3-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonyl fluoride; 4-methoxy-3-{{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonyl fluoride; 3'-(2-{{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)-1,1'-biphenyl-4-carbonitrile; 3'-(2-{{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)-1,1'-biphenyl-3-carboxylic acid; 3'-(2-{{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)-1,1'-biphenyl-3-carbonitrile; N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-amine; N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-quinolin-3-ylphenyl)-1,3-oxazol-2-amine; N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(5-methylthien-2-yl)phenyl]-1,3-oxazol-2-amine; N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(1*H*-indol-5-yl)phenyl]-1,3-oxazol-2-amine; methyl 3'-(2-{{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)-1,1'-biphenyl-4-carboxylate;

3-{{[5-(3'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxy-N-methylbenzenesulfonamide;

3-{{[5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonyl fluoride;

3-{{[5-(3'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonamide;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(2'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-amine;

5-(2'-chloro-1,1'-biphenyl-3-yl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

4-methoxy-N-methyl-3-{{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

N-ethyl-4-methoxy-3-{{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

4-methoxy-3-{{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

N-isopropyl-4-methoxy-3-{{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

N-(cyclopropylmethyl)-4-methoxy-3-{{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

N,N-diethyl-4-methoxy-3-{{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

N-isopropyl-4-methoxy-3-{{[5-(3-pyridin-3-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

3-{{[5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-N-isopropyl-4-methoxybenzenesulfonamide;

3-{{[5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxy-N,N-dimethylbenzenesulfonamide;

3-{{[5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-N-cyclopropyl-4-methoxybenzenesulfonamide;

3-{{5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-N-butyl-4-methoxybenzenesulfonamide;

3-{{5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-N,N-diethyl-4-methoxybenzenesulfonamide;

3-{{5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxy-N-(tetrahydrofuran-2-ylmethyl)benzenesulfonamide;

4-[3-(2-{{5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenyl]-N-isopropylpyrimidin-2-amine;

N-benzyl-4-[3-(2-{{5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenyl]pyrimidin-2-amine;

N'-{4-[3-(2-{{5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenyl]pyrimidin-2-yl}-N<sup>a</sup>,N<sup>b</sup>-dimethylpropane-1,3-diamine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-phenylpyrimidin-4-yl)phenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-isopropylpyrimidin-4-yl)phenyl]-1,3-oxazol-2-amine;

5-[3-(2-tert-butylpyrimidin-4-yl)phenyl]-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

3'-(2-{{5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)-1,1'-biphenyl-4-carboxylic acid;

3'-(2-{{5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)-N-(2-morpholin-4-ylethyl)-1,1'-biphenyl-4-carboxamide; and

3'-(2-{{5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)-N-[3-(4-methylpiperazin-1-yl)propyl]-1,1'-biphenyl-4-carboxamide;

or a salt, solvate, or physiologically functional derivative thereof.

6. A pharmaceutical composition, comprising: a therapeutically effective amount of a compound as claimed in any one of claims 1 to 5, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

7. The pharmaceutical composition of claim 6, further comprising at least one additional anti-neoplastic agent.
8. The pharmaceutical composition of claim 7, further comprising an additional agent which inhibits angiogenesis.
9. A method of treating a disorder in a mammal, said disorder being mediated by inappropriate VEGFR2, CDK2, and/or CDK4 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 to 5, or a salt, solvate, or a physiologically functional derivative thereof.
10. The method of claim 9, wherein the disorder is cancer.
11. A method of treating a disorder in a mammal, said disorder being mediated by inappropriate VEGFR2 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 to 5, or a salt, solvate, or a physiologically functional derivative thereof.
12. The method of claim 11, wherein the disorder is cancer.
13. A method of treating a disorder in a mammal, said disorder being mediated by inappropriate CDK2 and/or CDK4 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 to 5, or a salt, solvate, or a physiologically functional derivative thereof.
14. The method of claim 13, wherein the disorder is cancer.
15. A compound as claimed in any of claims 1 to 5, or a salt, solvate, or a physiologically functional derivative thereof for use in therapy.

16. Use of a compound as claimed in any of claims 1 to 5, or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder mediated by inappropriate VEGFR2 activity and/or inappropriate CDK2 and/or CDK4 activity.
17. The use of claim 16, wherein the disorder is cancer.
18. Use of a compound as claimed in any of claims 1 to 5, or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder mediated by inappropriate VEGFR2 activity.
19. The use of claim 18, wherein the disorder is cancer.
20. Use of a compound as claimed in any of claims 1 to 5, or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder mediated by inappropriate CDK2 and/or CDK4 activity.
21. The use of claim 20, wherein the disorder is cancer.
22. A method of treating cancer in a mammal, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 to 5, or a salt, solvate, or a physiologically functional derivative thereof.
23. The method of claim 22, further comprising administering a therapeutically effective amount of at least one additional anti-cancer therapy.
24. The method of claim 23, wherein the additional anti-cancer therapy is administered concomitantly with the administration of the compound, salt, solvate or physiologically functional derivative as claimed in any one of claims 1 to 5.

25. The method of claim 23, wherein the additional anti-cancer therapy is administered after the administration of the compound, salt, solvate or physiologically functional derivative as claimed in any one of claims 1 to 5.

26. The method of claim 25, wherein the additional anti-cancer therapy is administered before the administration of the compound, salt, solvate or physiologically functional derivative as claimed in any one of claims 1 to 5.

27. A method of treating a disorder in a mammal, said disorder being mediated by inappropriate VEGFR2 activity, comprising: administering to said mammal therapeutically effective amounts of (i) a compound as claimed in any one of claims 1 to 5, or a salt, solvate or physiologically functional derivative thereof and (ii) an agent to inhibit growth factor receptor function.

28. The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of platelet derived growth factor receptor.

29. The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of epidermal growth factor receptor.

30. The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of the erbB2 receptor.

31. The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of a VEGF receptor.

32. The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of the TIE-2 receptor.

33. The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of the epidermal growth factor receptor and erbB2.

34. The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of at least two of the epidermal growth factor receptor, erbB2, and erbB4.
35. The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of the VEGF receptor and the TIE-2 receptor.
36. The method of claim 27, wherein the disorder is cancer.
37. A method of treating a disorder in a mammal, said disorder being characterized by inappropriate angiogenesis, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 to 5, or a salt, solvate or physiologically functional derivative thereof.
38. The method of claim 37, wherein the inappropriate angiogenesis results from at least one of inappropriate VEGFR1, VEGFR2, VEGFR3 or TIE-2 activity.
39. The method of claim 37, wherein the inappropriate angiogenesis results from inappropriate VEGFR2 and TIE-2 activity.
40. The method of claim 37, further comprising administering a therapeutically effective amount of a TIE-2 inhibitor.
41. The method of claim 37, further comprising administering an agent to inhibit growth factor receptor function.
42. The method of claim 37, wherein the disorder is cancer.

43. Use of a compound as claimed in any of claims 1 to 5, or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder characterized by inappropriate angiogenesis.

44. A method of treating a disorder in a mammal, said disorder being mediated by inappropriate CDK2 and/or CDK4 activity, comprising: administering to said mammal therapeutically effective amounts of (i) a compound as claimed in any one of claims 1 to 5, or a salt, solvate or physiologically functional derivative thereof and (ii) an agent to inhibit growth factor receptor function.